Emergent Biosolutions Inc [NYSE: EBS] surged by $0.09 during the normal trading session on while it closed the day at $3.98.
Emergent Biosolutions Inc stock has also gained 110.58% of its value over the past 7 days. However, EBS stock has inclined by 160.13% in the 3 months of the year. Over the past six months meanwhile, it has gained 87.74% and gained 65.83% year-on date.
The market cap for EBS stock reached $208.55 million, with 52.20 million shares outstanding and 50.47 million shares in the current float. Compared to the average trading volume of 5.71M shares, EBS reached a trading volume of 9371702 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Emergent Biosolutions Inc [EBS]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for EBS shares is $5.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on EBS stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
The Benchmark Company have made an estimate for Emergent Biosolutions Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on March 07, 2024. While these analysts kept the previous recommendation, JP Morgan raised their target price to Underweight. The new note on the price target was released on November 20, 2023, representing the official price target for Emergent Biosolutions Inc stock.
The Average True Range (ATR) for Emergent Biosolutions Inc is set at 0.42, with the Price to Sales ratio for EBS stock in the period of the last 12 months amounting to 0.18. The Price to Book ratio for the last quarter was 0.31, with the Price to Cash per share for the same quarter was set at 1.51.
EBS stock trade performance evaluation
Emergent Biosolutions Inc [EBS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 110.58. With this latest performance, EBS shares gained by 73.80% in over the last four-week period, additionally plugging by 87.74% over the last 6 months – not to mention a drop of -53.40% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for EBS stock in for the last two-week period is set at 79.31, with the RSI for the last a single of trading hit 86.28, and the three-weeks RSI is set at 73.43 for Emergent Biosolutions Inc [EBS]. The present Moving Average for the last 50 days of trading for this stock 2.51, while it was recorded at 3.00 for the last single week of trading, and 3.00 for the last 200 days.
Emergent Biosolutions Inc [EBS]: An insightful look at the core fundamentals
Emergent Biosolutions Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.55 and a Current Ratio set at 1.08.
Emergent Biosolutions Inc [EBS]: Institutional Ownership
The top three institutional holders of EBS stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.4983%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $200.69 billion in EBS stocks shares; and BERKSHIRE HATHAWAY INC, currently with $174.35 billion in EBS stock with ownership which is approximately 5.8386%.
